B. Riley Securities resumed coverage on OptimizeRx with a new price target
$OPRX
Business Services
Consumer Discretionary
B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $30.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $7.00 → $6.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 12/20/2024 | $5.50 | Equal-Weight | Stephens |
| 7/25/2024 | $18.50 | Buy | B. Riley Securities |
| 4/4/2024 | $15.00 | Mkt Outperform | JMP Securities |
| 1/3/2024 | $15.00 | Equal Weight | Barclays |
| 2/2/2023 | $30.00 | Buy | B. Riley Securities |
| 11/1/2022 | $19.00 | Buy | Stifel |
| 7/15/2022 | $38.00 | Outperform | SVB Leerink |
4 - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
SCHEDULE 13G/A - OptimizeRx Corp (0001448431) (Subject)
8-K - OptimizeRx Corp (0001448431) (Filer)
8-K - OptimizeRx Corp (0001448431) (Filer)
4 - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously
Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50
B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50
WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company's Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro joined the Company in 2019 and has been the Company's CEO since March 2025, after serving as the interim CEO from January 2025. The appointment of Mr. Silvestro, with his knowledge of the Company and expertise in the industry, will enhance overall leadership and gre
WALTHAM, Mass., April 18, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx's ongoing process to refresh and expand its board of directors (the "Board"), it intends to appoint a new independent director to its Board of Directors during the second half of this year. With the appointment of a new independent director in 2025, OptimizeRx will have refreshed its Board, which is currently comprised of five directors, with three new directors since 2020, including Catherine Klema w
WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has appointed Steve Silvestro as the Company's new Chief Executive Officer, effective March 10, 2025. Mr. Silvestro brings to OptimizeRx more than 20 years of experience in building and managing health technology and services companies, and has served as an executive at OptimizeRx since joining the Company in 2019. His career includes strategic development, sales leadership, technology and product innovation, and M&A within a
WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Thursday, August 7, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)T
Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended March 31, 2025. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the first quarter of 2025
WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Monday, May 12, 2025, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Monday, May 12, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Toll Free
SC 13G/A - OptimizeRx Corp (0001448431) (Subject)
SC 13G - OptimizeRx Corp (0001448431) (Subject)
SC 13G/A - OptimizeRx Corp (0001448431) (Subject)
WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Thursday, August 7, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)T
WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company's Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro joined the Company in 2019 and has been the Company's CEO since March 2025, after serving as the interim CEO from January 2025. The appointment of Mr. Silvestro, with his knowledge of the Company and expertise in the industry, will enhance overall leadership and gre
Strategic Collaboration Brings Precision Micro-Neighborhood® Targeting Healthcare Consumer Audiences to Linear and Connected TV Simulmedia, a national leader in data-driven TV and streaming advertising, today announced a strategic partnership with OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions, to enable the self-serve availability of Micro-Neighborhood® Targeting (MNT) audiences across linear, digital, and connected TV (CTV) channels. This collaboration allows healthcare brands—especially small and mid-size pharmaceutical companies and in-house planning teams—to activate clinically precise audiences across guaranteed premium TV and streaming inven